After over a year of delays, on February 8, 2013 the Centers for Medicare and Medicaid Services (CMS) published its regulations (Final Rule) implementing the Transparency Reports and Reporting of Physician Ownership or Investment Interests statute, a key facet of the Affordable Care Act known more commonly as the Sunshine Act. The Final Rule was first issued on February 1, 2013 after the release of the Proposed Rule in December 2011 and the myriad industry comments that followed.
The Final Rule maintains the Proposed Rule's significant and far-reaching financial disclosure obligations for drug manufacturers, their affiliates, physicians (including dentists, podiatrists, optometrists and chiropractors) and certain teaching hospitals. The Sunshine Act generally requires manufacturers and their affiliates (applicable manufacturers) of drugs and other products covered under federal health programs (covered products) to report payments or other transfers of value to physicians and teaching hospitals (covered recipients). It further requires manufacturers and group purchasing organizations to disclose certain ownership and investment interests.
Regulators hope the Sunshine Act will increase transparency and deter financial relationships between drug manufacturers and providers that drive up the cost of health care. Affected providers and entities must begin collecting relevant data on August 1, 2013 and must report the data back to CMS no later than March 31, 2014. Some of the Final Rule's most significant changes include:
Applicable Manufacturers
The Sunshine Act defines an "applicable manufacturer" as an entity that operates in the United States and falls within one of two categories: